



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 33/00, 27/00		A1	(11) International Publication Number: WO 98/10806
			(43) International Publication Date: 19 March 1998 (19.03.98)
<p>(21) International Application Number: PCT/US97/16163</p> <p>(22) International Filing Date: 11 September 1997 (11.09.97)</p> <p>(30) Priority Data: 08/713,800 13 September 1996 (13.09.96) US</p> <p>(71) Applicant: MEADOX MEDICALS, INC. [US/US]; 112 Bauer Drive, Oakland, NJ 07436 (US).</p> <p>(72) Inventors: PATNAIK, Birendra, K.; 13 South Gables Drive, Chester, NJ 07930 (US). LIN, Horng-Ban; 9 Willow Drive, Randolph, NJ 07869 (US). LENTZ, David, J.; 140 Hidden Road, Andover, MA 01810 (US). ZDRAHALA, Richard, J.; 9641 Yukon Avenue, South, Bloomington, MN 55438 (US).</p> <p>(74) Agents: SCOLA, Daniel, A., Jr. et al.; Hoffmann & Baron, 350 Jericho Turnpike, Jericho, NY 11753 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ePTFE SMALL CALIBER VASCULAR GRAFTS WITH SIGNIFICANT PATENCY ENHANCEMENT VIA A SURFACE COATING WHICH CONTAINS COVALENTLY BONDED HEPARIN</p> <p>(57) Abstract</p> <p>Disclosed are implantable medical devices with enhanced patency. Expanded polytetrafluoroethylene small caliber vascular grafts coated with polymer bound bio-active agents that exhibit enhanced patency are disclosed. Methods of preparing same are also provided.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**ePTFE SMALL CALIBER VASCULAR GRAFTS WITH SIGNIFICANT
PATENCY ENHANCEMENT VIA A SURFACE COATING WHICH
CONTAINS COVALENTLY BONDED HEPARIN**

FIELD OF INVENTION:

The present invention generally relates to implantable medical devices with enhanced patency. More particularly, the present invention relates to ePTFE small caliber vascular grafts that have significantly enhanced patency when coated with polymer bound bio-active agents and methods of applying these agents to such grafts.

5

BACKGROUND OF THE INVENTION:

It is well known to use bio-active materials to coat structures to be introduced into a living system. Over the last 30 years, research into this area has become 10 increasingly important with the development of various bio-compatible articles for use in contact with blood, such as, for example, vascular grafts, artificial organs, endoscopes, cannulas, and the like.

15 While various materials have been used to make such articles, synthetic polymers have been increasingly popular as the preferred materials due to their anti-thrombogenic and good mechanical properties. For example, polyurethane is a useful and effective material with a variety of clinical applications. Although synthetic polymers, such as, PTFE and polyurethane, are less thrombogenic than earlier materials, thrombus formation is still a problem.

A thrombus is the formation of a solid body composed of elements of the blood, 20 e.g., platelets, fibrin, red blood cells, and leukocytes. Thrombus formation is caused by blood coagulation and platelet adhesion to, and platelet activation on, foreign substances. When this occurs, a graft is occluded by such thrombogenic material, which in turn, results in decreased patency for the graft. Accordingly, more stringent selection criteria are necessary for small caliber vascular graft materials because the small diameters of 25 these grafts magnify the problem of deposition of such thrombogenic material on the luminal surfaces of the graft. Thus, thrombus formation is a serious complication in surgery and clinical application of small caliber vascular grafts.

5

Various anti-thrombogenic agents, such as heparin, have been developed and incorporated into bio-compatible articles to combat thrombus formation. In a living system, heparin inhibits the conversion of a pro-enzyme (prothrombin) to its active form (thrombin). Thrombin catalyzes a complicated biochemical cascade which ultimately leads to the formation of a thrombus.

10

Infection is also a serious concern for articles to be implanted into a host organism. Bacterial, viral and other forms of infection may lead to life-threatening complications when an article is implanted into a host organism. Thus, binding of an anti-infection agent to a surface of an implantable article can reduce the risk of

10

infection when such an article is introduced into a host organism.

15

The art is replete with various procedures for preventing thrombus formation and/or infection by modifying polymeric surfaces. Various substrate surfaces have previously been described that are suitable for introducing into a biological system. For example, bio-compatible polymer surfaces have been described with various benefits including decreased thrombogenicity, increased abrasion-resistance and improved hydrophilic lubricious properties. Additionally, U.S. Patent No. 5,061,777 describes procedures for modifying polyurethanes and polyurethaneureas in order to decrease their thrombogenicity. Similarly, U.S. Patent No. 5,077,352 describes a method of forming a polyurethane complexed with a poly(ethylene oxide) having good adherence to a substrate and good anti-friction properties.

20

These polymer surfaces, however, are not completely bio-compatible.

25

Thrombus formation and infection continue to pose problems when such articles are implanted within a host. These articles especially are not suitable for use with small caliber vascular grafts where graft patency is critical. Thus, procedures for grafting bio-active agents onto a substrate surface have been developed.

30

For example, bio-active agents directly bound to the polymer backbone of a polymer coating material are known. Hu et al. in U.S. Patent No. 5,077,372 disclose a medical device coated with an anti-thrombogenic agent, e.g., heparin, covalently linked to the amino groups of the polyurethane coating. These coating reactions and heparinizations are carried out directly on the device's surface. Such methods, however, suffer from decreased bio-activity, and consequently, increased thrombogenicity because the bio-active agent, such as, heparin, must be positioned at a

distance from the substrate surface in order to optimally interact with its physiological substrates.

Accordingly, alternative methods have been developed for binding bio-active molecules to substrate surfaces. In particular, methods for ionically binding bio-active agents to a substrate via a quarternary ammonium compound have been described. See for example, Mano in U.S. Patent No. 4,229,838; Williams et al. in U.S. Patent No. 4,613,517; McGary et al. in U.S. Patent No. 4,678,660; Solomon et al. in U.S. Patent No. 4,713,402; and Solomon et al. in U.S. Patent No. 5,451,424,

These methods, however, are severely limited because the bio-active agent is leached over time from the surface of the substrate. Thus, the protection afforded by the ionically bound bio-active agent is transient at best. Such procedures, therefore, also are not suitable for small caliber grafts.

Accordingly, more permanent methods for binding bio-active molecules to substrate surfaces have also been developed. These methods include covalently binding a bio-active molecule, either directly, or via a spacer molecule, to a substrate surface. For example, photochemical reactions are described which covalently bind bio-active agents to substrate surfaces. See U.S. Patent Nos. 4,331,697; 4,973,493; 4,979,959; and 5,258,041. When photochemical reactions are used to covalently bind bio-active agents to substrates, however, the choice of substrate is limited. Actinic radiation causes certain substrates, for example PTFE, to degrade. Thus, these methods are limited by the substrate material to be coated.

Even though photochemical reactions are limited to use with certain actinic radiation-resistant substrates, these reactions have been used to indirectly bind bio-active coatings to such substrates via a spacer molecule. For example, several studies describe polyurethane coatings having various spacer molecules that link bio-active agents to polymer substrates. These studies indicate that bio-active agents, such as, for example, heparin, bound to polymer coatings retain more of their bio-activity if they are tethered away from the surface of an article by a spacer.

Thus, Bichon et al. in U.S. Patent No. 4,987,181 describe a substrate having an adhesive film with anti-thrombogenic properties on its surface. This adhesive film is an olefinic copolymer having carboxylic side chains of the formula $O=CH-NH_2-(CH_2)_n-NH_2-CH_2-R$, wherein R is a heparin molecule or a depolymerization fragment of a

heparin molecule. The adhesive film is deposited onto the substrate via photo-initiated polymerization of a suitable monomer. Thus, heparin, or a fragment thereof, is covalently linked to the substrate via an amine spacer.

Although covalent bonding of the bio-active agent to the substrate surface with, or without, a spacer molecule therebetween solves certain problems in the art, these methods continue to be limited. In particular, certain bio-active coatings begin to degrade in response to the photochemical signals used to bind them to the substrate surfaces. In a similar fashion, certain polymeric substrates, such as, polytetrafluoroethylene, degrade when exposed to photochemical reactions and are therefore not useful with such coatings. Thus, attempts have been made to use spacer molecules to bind bio-active agents to substrate surfaces without photochemical reactive groups.

For example, in a four step process, Park et al. disclose immobilizing heparin onto a commercial preparation of a segmented polyetherurethaneurea (PUU) using hydrophilic poly(ethylene oxide) (PEO) spacers of different molecular weights. Their method includes (1) coupling hexamethyldiisocyanate (HMDI) to a segmented polyurethaneurea backbone through an allophanate/biuret reaction between the urethane/urea-nitrogen proton and one of the isocyanate groups on the HMDI. Next, (2) the free isocyanate groups attached to the backbone are then coupled to a terminal hydroxyl group on a PEO to form a PUU-PEO complex. Next (3) the free hydroxyl groups of the PUU-PEO complex are treated with HMDI to introduce a terminal isocyanate group. Finally, (4) the NCO functionalized PUU-PEO is then covalently bonded to reactive functional groups on heparin (-OH and -NH₂) producing a PUU-PEO-Hep product. K.D. Park and S.W. Kim, "PEO-Modified Surfaces-In Vitro, Ex Vivo and In Vivo Blood Compatibility", in Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications 283 (J. Milton Harris ed. 1992). This method will be referred to hereinafter as the "Park Method."

Although the use of spacer molecules to tether bio-active molecules to substrate surfaces increases the anti-thrombogenicity of certain substrate surfaces, problems still arise in applying such coatings to chemically inert substrates, such as PTFE, PET and the like. These coatings, which have hydrophilic properties adhere weakly, if at all, to hydrophobic chemically inert substrate surfaces. Thus, the natural repulsive forces

between the hydrophilic coatings and the hydrophobic substrate surface serves to decrease the ability of the coating to remain secured to the substrate surface. Thus, plasma treatment of substrate surfaces has been developed as a method to alter the surface properties of such substrates in order to secure coatings thereto.

5 Accordingly, surfaces of chemically inert tubes have been modified in order to promote binding between a coating and the substrate surface by deposition of a thin layer of an appropriate polymer onto the substrate surface using plasma polymerization (also known as glow discharge) techniques. This technique involves introducing a polymerizable organic monomer in a gaseous state into a vacuum container together
10 with the substrate material to be coated. The gas is then subjected to an electric discharge which initiates a polymerization reaction. This reaction generates ions or free radicals which react with and deposit on the substrate. The polymer formed is normally deposited as a thin layer over the substrate material present in the reaction vessel.
15 Critically, the bulk substrate characteristics are preserved, but the surface properties, which are major determinants of bio-compatibility and non-thrombogenicity, can be modified or improved by plasma polymerization.

Accordingly, Hu et al. in U.S. Patent No. 4,720,512 describe a method for imparting improved anti-thrombogenic activity to a polymeric support structure by coating it with an amine-rich material, e.g., polyurethaneurea, introducing hydrophobic groups into the amine-rich surface coating through plasma treatment with fluorine compounds, and covalently bonding an anti-thrombogenic agent to the hydrophobic amine-rich surface. Similarly, Hu et al. in U.S. Patent No. 4,786,556 describe substituting siloxane and silazane compounds during the plasma treatment step of the '512 patent for the previously disclosed fluorine compounds. See also, Narayanan et al. in U.S. Patent Nos. 5,132,108 and 5,409,696 and Feijen et al. in U.S. Patent No. 5,134,192 for other examples of plasma treating substrates prior to introduction of a bio-active molecule.

30 These preceding methods for plasma treating a substrate surface are limited in their scope because they only work with certain substrates. Thus, they do not provide a general purpose coating composition that can bind to a variety of substrate surfaces.

 All of these disclosures have addressed substrate surfaces and/or coatings therefor which can exist within biological systems and, in particular, can increase the

anti-thrombogenicity of the surface of, e.g., medical articles. These reactions, however, cannot be universally applied to substrate surfaces. Accordingly, when chemically inert ePTFE vascular grafts are desired to be used, they must be implanted without the benefit of, e.g., an anti-thrombogenic coating, or with one of the previously described coatings. In either case, the patency of the graft is severely compromised because foreign bodies build up on and occlude the graft. This is especially problematic in small caliber grafts where the diameter of the lumen is smaller than other larger diameter vascular grafts. Thus, there is a need for a chemically inert vascular graft material with increased patency and methods of making such a graft. In particular, there is a need for a chemically inert small caliber vascular graft having a surface that adheres well to bio-active coatings applied thereto. The present invention is directed toward providing such a solution.

SUMMARY OF THE INVENTION

The present invention relates to implantable medical devices with enhanced patency. In particular, the present invention is directed to an implantable medical device having at least one hydrophobic surface that includes a bio-active coating bound thereto. The bio-active coating contains a polymer backbone bound via an amide or amine chemical bond to one end of a hydrophilic, amine terminated spacer that has at least one amine group at its first and second ends. A bio-active molecule is covalently bound to the unreacted end of the hydrophilic spacer. The hydrophilic spacer is repelled by the hydrophobic surface of the medical device in such a way that the bio-active molecule is extended away from the hydrophobic surface.

In the present invention, the bio-active agent further includes a polymer structure which is defined by a bio-compatible polymeric backbone and at least one pendant moiety of the general formula $R^1-R^2-NH-C-R^3$. In this formula, R^1 is $O=C-NH$ or NH . R^2 is a spacer group selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides. R^3 is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotic agents, antibacterial agents, antiviral agents, their pharmaceutical salts and mixtures.

thereof.

In the present invention, any medical device may be used. Preferably the medical device of the present invention is an implantable device such as a vascular graft, endoprosthesis or stent. Other medical devices may also be used, such as, catheters which are minimally invasive. The vascular graft may include a hollow tubular body having an inner and an outer hydrophobic surface. More preferably, the device of the present invention is a small caliber vascular graft and most preferably an ePTFE vascular graft. For purposes of this invention, the term "vascular graft" is meant to include endoprostheses which are generally introduced via catheter.

In another embodiment of the present invention, a medical device is provided that includes a bio-active coating over a body fluid contacting surface of the medical device for contacting body fluids. In this embodiment of the invention, the body fluid contacting surface is covalently bonded to the bio-active coating. The bio-active coating includes a polymeric structure defined by a bio-compatible polymeric backbone and at least one pendant moiety of the general formula $R^1-R^2-NH-C-R^3$. In this formula, R^1 is $O=C-NH$ or NH . R^2 is a spacer group having a chain length of about 9 to about 400 atoms (approximately 100 daltons to 200,000 daltons). Preferably the spacer group has a chain length from about 60 to about 250 atoms. For example, the spacer group may include oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides. R^3 is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics agents, antibacterial agents, antiviral agents, their pharmaceutical salts and mixtures thereof.

In yet another embodiment of the invention, there is provided a surface-modified implantable sheet material whose treated surface when exposed to a body fluid is antithrombogenic over extended periods of time. This implantable sheet material includes a hydrophobic substrate material having a plasma induced hydrophilic functionality and a bio-active coating covalently bonded thereto. The sheet can be formed into surgical mesh patches or plugs for tissue and muscle defects, such as, hernias. The bio-active coating has a polymeric structure defined by a bio-compatible polymeric backbone and at least one pendant moiety selected from the group consisting of $R^1-R^2-NH-C-R^3$, wherein R^1 is $O=C-NH$ or NH . R^2 is a spacer group having a chain

length of about 9 to about 400 atoms (approximately 100 daltons to about 200,000 daltons). Preferably the spacer group has a chain length from about 60 to about 250 atoms. For example, the spacer group may include oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides. R³ is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics, antibacterial agents, antiviral agents, their pharmaceutical salts and mixtures thereof.

In a further embodiment of the present invention, the medical device having at least one hydrophobic surface has a bio-active coating thereon which is the reaction product of a polymeric backbone, an amine-terminated hydrophilic spacer and a bio-active agent. This product is initiated by a first reaction that includes reacting in the presence of a first dehydrating agent a bio-compatible polymer backbone containing one or more functional groups selected from the group consisting of carboxyl functionality, unsaturated functionality and mixtures thereof with a hydrophilic, amine-terminated spacer having at least one amine group at its first and second ends. In this first reaction, one of the amine groups reacts with one or more functional groups in the polymer backbone to bond the spacer to the polymer backbone. The bio-active coating includes a second reaction in which a bio-active agent is reacted with the remaining unreacted amine terminated end of the spacer in the presence of a second dehydrating agent, which may be the same or different as the first dehydrating agent, to covalently bind the bio-active agent to the spacer.

Application of the bio-active coating is by conventional methods which are known in the art. These methods include, without limitation, dipping, steeping and spraying the article with the bio-active coating. Additional coating and impregnation techniques using pressure to force the coating into the substrate interstices are also contemplated. Multiple layers of the bio-active coating may be applied to the article. Preferably, from about 1 to about 10 layers of the polymer bound bio-active agent are applied to the surface of the article.

In another embodiment of the invention the luminal surface of an article, such as an ePTFE graft, is plasma treated so that hydrophilic groups generated from a gaseous material are introduced onto the surface thereof. Any plasma treatment which


is capable of introducing hydrophilic groups onto the surface of an ePTFE vascular graft is useful. It is preferred that a hydrogen-rich plasma be used. Next, the plasma treated surface is contacted with a bio-active coating. The bio-active coating is the reaction product of a first reaction that includes reacting in the presence of a first dehydrating agent a biocompatible polymer backbone containing one or more functional groups selected from the group consisting of carboxyl functionality, unsaturated functionality and mixtures thereof with a hydrophilic amine-terminated spacer having a first end and a second end. The first and second ends of the hydrophilic spacer each have an amine group wherein one of the amine groups reacts with one or more functional groups on the polymer backbone in the presence of a dehydrating agent. This method further includes a second reaction in which a bio-active agent reacts with the remaining unreacted amine-terminated end of the spacer in the presence of a second dehydrating agent to covalently bind the bio-active agent to the spacer.

In this method, the luminal surface of the ePTFE vascular graft includes nodes and fibrils that are resistant to plasma treatment. That is, plasma treatment will not degrade this structure. Conventional plasma treatment, which is known in the art, is useful in this method. For example, the plasma treatment may take place in a plasma ionization chamber with the following parameters: a) a gas flow rate of about 1 to 500 ml/minute; b) a chamber pressure of about 0.1 to about 100 torrs; c) a power setting of about 1 to 700 watts; and d) a sample exposure time of from about 1 minute to about 24 hours.

In a still further embodiment of the present invention, a method of imparting a bio-active coating to a surface of an article is provided. This method includes plasma treating a surface of the article together with a gaseous material in an ionization chamber so that hydrophilic groups generated from the gaseous material are introduced onto a surface of the article in order to provide a hydrophilic environment thereon. Then, the surface is contacted with a coating composition that includes a polymeric structure defined by a bio-compatible polymeric backbone and at least one pendant moiety selected from the group consisting of $R^1-R^2-NH-C-R^3$, wherein R^1 is $O=C-NH$ or NH , R^2 is a spacer group having from about 9 to about 400 atoms (approximately 100 daltons to about 200,000 daltons) and preferably from about 60 to about 250 atoms. R^2 is further selected from the group consisting of oxygenated polyolefins, aliphatic

polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides. R³ is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics agents, antiviral agents, their pharmaceutical salts and mixtures thereof.

In a further embodiment of the invention, another method of imparting a bio-active coating to a surface of an article is provided. This method includes plasma treating the surface of the article together with a gaseous material in an ionization chamber so that hydrophilic groups generated from the gaseous material are introduced onto the surface of the article in order to provide a hydrophilic environment thereon. Then, the surface is contacted with a polymer bound bio-active composition represented by the structure:



20

15

25

30

wherein P is a bio-compatible polymer selected from the group consisting of bio-compatible polymers having carboxyl functionality, unsaturated functionality, and mixtures thereof; R¹ is O=C-NH or NH; R² is a hydrophilic amine-terminated spacer selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides; and R³ is a bio-active agent selected from the group consisting of anti-thrombogenic agents, antibiotic agents, antibacterial agents, their pharmaceutical salts, and mixtures thereof.

The bio-active agent useful in the present invention may be chosen from a wide variety of materials. Examples include agents selected from the group consisting of

antithrombogenic agents, antibiotic agents, antibacterial agents, antiviral agents, their pharmaceutical salts, and mixtures thereof. Furthermore, the bio-active agent is selected from the group consisting of heparin, prostaglandins, urokinase, streptokinase, sulfated polysaccharide, albumin, their pharmaceutical salts and mixtures thereof.

5

DETAILED DESCRIPTION OF THE INVENTION

While this invention is satisfied by embodiments in many different forms, there will be described herein in detail preferred embodiments of the invention, with the understanding that the present disclosure is to be considered as exemplary of the principles of the invention and is not intended to limit the invention to the embodiments illustrated and described. The scope of the invention will be measured by the appended claims and their equivalents.

In accordance with the present invention, there are provided novel plasma treated chemically inert substrates with bio-active coatings and their use in developing antithrombogenic and/or anti-infective articles. More particularly, new bio-active coatings prepared by novel reaction schemes are provided for ePTFE vascular grafts. Also provided are methods for applying heparinized polymers as antithrombogenic coatings in, e.g., small caliber ePTFE vascular grafts.

The bio-active coatings and methods described herein are particularly advantageous over previously disclosed polymer coatings because the composition and structure of the present coatings are more controllable and reproducible. In addition, the properties of the bio-active coating of the present invention can be varied easily, e.g., biostability, hydrophilicity etc. Also, the methods of synthesizing the present bio-active coatings are more efficient and take less time than previously disclosed methods. Another advantage of the present invention is that the reactions may be carried out at lower temperatures. Importantly, the reaction schemes of the present invention form fewer cross-links and provide higher polymer yields than previously described methods. Thus, these new coatings are well suited for application onto, for example, the luminal surface of a small caliber vascular graft.

The present invention contemplates coating implantable medical devices with bio-active coatings described herein. Any type of implantable device may be used with the present invention, such as, for example, vascular grafts. The bio-active coatings of

the present invention have been formed to be particularly useful in several caliber grafts where patency is especially critical. Such grafts are advantageous because these bio-active coatings enable the grafts to function with significantly enhanced patency. Thus, these small caliber vascular grafts may be used in areas of the body where conventional sized grafts are contraindicated. As used herein, "small caliber" means an inner tube diameter of 5.0 mm or less. Such small caliber grafts are especially useful in cerebral or coronary blood vessel by-pass procedures.

Synthetic polymers used for vascular grafts include polyester, e.g. polyethylene terephthalate, polyurethane, and polytetrafluoroethylene, among others. The graft must have a blood contacting (luminal) surface which is considered to have hydrophobic character whereby the pendent group containing the hydrophobic spacer and bio-active agent are repelled away from the synthetic polymer surface by the natural repulsion forces between hydrophobic and hydrophilic groups. These natural repulsion forces make the bio-active agent more available for interaction with the blood and more efficient for carrying out such functions as enhancing antithrombogenicity and the like. Thus, although the coatings are intended to be particularly useful in small caliber ePTFE vascular grafts, use in both small and large sized grafts made of various polymers are contemplated.

Grafts formed of ePTFE have a fibrous structure which is defined by interspaced nodes interconnected by elongated fibrils. The spaces between the node surfaces that are spanned by the fibrils are defined as the internodal distance (IND). The art is replete with examples of vascular grafts made of microporous ePTFE tubes useful as vascular grafts. The porosity of an ePTFE vascular graft is controlled by varying the IND of the microporous structure of the tube. An increase in the IND within a given structure results in enhanced tissue ingrowth, as well as cell endothelialization, along the inner surface thereof. This tissue ingrowth and endothelialization promotes stability, enhances radial strength and increases the patency of the graft. Thus, the presence of intact nodes and fibrils on ePTFE surfaces is critical for the long-term function of this substrate.

The node and fibril structure of the ePTFE grafts of the present invention remain intact even after plasma treatment. Thus, plasma treating the grafts of the present invention does not appear to substantially affect the physical structure of the

ePTFE graft. Accordingly, plasma treatment would not be expected to reduce the long-term patency or ability of these grafts to support tissue ingrowth.

Once an ePTFE vascular graft is plasma primed, one or more coatings of the present invention may be applied thereto. It should be noted that the internodal space, e.g., the space between the nodes that is not spanned by fibrils, is substantially covered by such coatings. Also, the elongated fibrils are substantially covered by such coatings. In contrast, where there are no fibrils in the IND, no bio-active coating is observed. This absence of coating material allows for cell ingrowth to occur without interference from such coatings.

Thus, the micro-structure of the inner surface of an ePTFE graft remains intact following plasma treatment and application of one or more coatings of the present invention. In particular, plasma priming the inner substrate surface followed by application of one or more layers of the bio-active polymer coating described herein does not destroy the ePTFE nodes or cleave the fibrils. Thus, the present invention does not interfere with, and in fact, improves the patency of an ePTFE graft. Therefore, such a graft is useful where small diameter grafts of ePTFE are required and the patency of such a graft must be ensured.

In order to ensure that the bio-active coatings described herein remain secured to the inner surface of the ePTFE graft, these surfaces are primed with a hydrogen-rich plasma prior to application of the bio-active coating. Providing organic surface coatings on substrate materials by means of plasma polymerization, as stated above, is known. For a review-type publication in this area, see an article by H. Yasuda, J. Macromol. Sci.-Chem., A10(3), pp. 383-420 (1976), entitled "Plasma for Modification of Polymers." According to Yasuda, plasma created by electric glow discharges contain a variety of species which are chemically active or energetic enough to cause chemical reactions, i.e., covalent bonding to a suitable substrate material.

As used herein, "plasma" is used in the sense of "low-temperature plasma" or "cold plasma" produced by glow discharges. Plasmas created by electric glow discharges contain a variety of species which are chemically active or energetic enough to cause chemical reactions, i.e., covalent bonding to a suitable substrate material. For example, electrons, ions of both charges, excited molecules at various levels of excitation, free radicals, and photons of various energies are created by cold plasma.

In a preferred embodiment, prior to deposition of the bio-active coating, the hydrophobic surface is treated with a hydrogen-rich plasma to provide better adhesion of the coating. This plasma treatment can be performed using conventional methods known in the art. For example, radio-frequency plasma polymer deposition of purified water vapor on untreated ePTFE tubes can be used. Purified water vapor is described but any hydrogen-rich material, such as, alcohols, diols, other polyhydroxy compounds, thiols, primary amines and secondary amines are useful. The ePTFE tubes are inserted into a glass vessel 75 cm in length and 10 cm in diameter, which is sealed. The vessel is evacuated by a mechanical pump, then back-filled with a hydrogen-rich gas, such as, for example, water vapor. The system pressure is monitored by a capacitance monometer connected to an adaptive pressure control system (AdapTorr™, a power supply model AC-2, controller model ACR-26, Vacuum General). Pressure is controlled by altering the position of an in-line adjustable butterfly valve. Brass capacitor rings are wrapped around the reactor and spaced 12 inches apart. The ePTFE tubes are placed anywhere in a 10-inch zone centered between the rings. A 13.56 MHZ RF generator (Tegal Corporation Novato, CA) is then turned on and a plasma formed. The gas flow rate is from about 1 ml/minute to about 500 ml/minute. The ePTFE tubes are etched with argon plasma (350 mtorr argon, 50 watts (W), 5 minutes) and then are treated with plasma for 10 minutes (water: 100 mtorr, 50 W) in the plasma reactor. Water vapor is continuously passed over the sample for one-half hour after the plasma reaction is terminated to quench any active surface groups. First argon, then air is bled into the reactor until the system returns to atmospheric pressure. The reactor is then opened under a laminar flow hood and the ePTFE tubes are removed.


The plasma-primed ePTFE grafts are then dipped, sprayed, steeped or otherwise contacted with one of the bio-active coatings described hereinbelow. As used herein, "contacting" the article to be coated with a coating of the present invention refers to these and other conventional methods of applying such coatings to a substrate surface. In addition, multiple bio-active coatings of the present invention may be applied. One particular method of coating or impregnating a graft involves filling it with the bio-active coating and applying pressure to force the coating into the interstices of the graft. Pressure or force can be applied using a number of mechanical means. Once coated, the grafts are allowed to dry and then are subjected to sterilizing conditions prior to

introduction into the body. Thus, the bio-active coatings of the present invention must be made of materials that can withstand such treatment and conditioning.

Accordingly, the polymer backbones of the present bio-active coatings are comb-type polymers in which bio-active molecules, such as heparin, are attached off of pendant groups. Preferred polymer backbones are siloxane-urethane copolymers, and most preferably, polyurethane and polyurethaneurea polymer backbones.


A composition of the invention was synthesized by reacting a polyol and a methyl diisocyanate to form a prepolymer. This prepolymer was reacted with a chain extender in the presence of a saturated carboxylic acid. Preferably, the chain extender is butanediol (BDO).

Preferably, the saturated carboxylic acid is



where R = alkyl of about 1 to about 10 carbon atoms; R' = alkyl of about 1 to about 10 carbon atoms; and R'' = alkyl or aryl of about 1 to about 10 carbon atoms. Preferably, R = R' = CH₂ and R'' = CH₃.

The resulting product was a polyurethane polymer containing carboxyl functionality (I). This polymer was then added to a hydrophilic amine-terminated poly(ethylene oxide), PEO, (II) in the presence of a dehydrating agent as indicated below:




25

The product (III) of the reaction indicated above is a polymer-spacer complex characterized by an amide linkage between the spacer and the polymer and an amine group on the free terminal end of the spacer. A bio-active agent, such as heparin, is

then covalently bound to the polymer-spacer complex in the presence of a dehydrating agent, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), as indicated below:

5




10

The product (IV) of the reaction indicated above is characterized by an amide linkage between the spacer and the bio-active molecule, e.g., heparin. Thus, in this embodiment, the reaction product IV is characterized by amide linkages between its respective units, i.e., between the polyurethane backbone and the spacer, and between the spacer and the bio-active agent. This composition and its method of synthesis will be referred to hereinafter as "Inventive Embodiment I."

15

In an another embodiment of this invention, a polyol and a methyl diisocyanate were reacted to form a prepolymer. This prepolymer was reacted with a chain extender in the presence of an unsaturated carboxylic acid. Preferably, the chain extender is BDO. Thus, in this embodiment, an unsaturated carboxylic acid is substituted for the saturated carboxylic of Inventive Embodiment I. Preferably the unsaturated carboxylic acid is




20

but others, such as any internally unsaturated alpha, omega-dicarboxylic acid (e.g., oleic acid or linoleic acid) are useful.


The resulting unsaturated polyurethane polymer containing carboxyl functionality was formed as illustrated below (V). This polymer was then added to a hydrophilic amine-terminated poly(ethylene oxide), PEO, (II) in the presence of a

dehydrating agent as indicated below:



The product (VI) of the reaction indicated above is an unsaturated polymer-spacer complex characterized by an amine linkage between the spacer and the polymer.

5 A bio-active agent then is grafted to the polymer-spacer complex in the presence of a dehydrating agent, such as, EDC as indicated below:



The product (VII) of the reaction indicated above is characterized by an amide linkage between the spacer and the bio-active molecule. Thus, in this embodiment, the reaction product VII is characterized by different linkages between its respective units,

i.e., an amine linkage between the polyurethane backbone and the spacer and an amide linkage between the spacer and the bio-active agent. This composition and its method of synthesis will be referred to hereinafter as Inventive Embodiment II.

In Inventive Embodiments I and II, dehydrating agents are used to facilitate the reaction in which the spacer is covalently bound to the polyurethane backbone. Preferably, the chemical bond formed therebetween is either an amide or amine chemical linkage. Similarly, dehydrating agents are used to facilitate the reaction in which the bio-active agent is covalently bound to the polyurethane backbone via the hydrophilic amine-terminated spacer. In this reaction, the linkage between the spacer and the bio-active agent is always an amide. Preferably, EDC increases the rate of reaction by removing water; however other dehydrating agents, such as dicyclohexylcarbodiimide, may also be used.

As Table 1 indicates, the present invention, e.g., Inventive Embodiments I and II, significantly improves upon previously described bio-active coating compositions and methods of making same, such as the aforementioned Park Method described herein.

TABLE 1

	Park Method	Inventive Embodiment I	Inventive Embodiment II
20	Polymer Yield (gm/gm starting material)	0.40 ± 0.5	1.05 ± 0.12
25	Level of Polymer Cross-Linking	Moderate (1-60)	Negligible-Low (0-15)
30	Factor Xa Heparin Activity µg/cm	0.03-0.13	0.3-0.09
			0.05

As illustrated in Table 1, the methods of the present invention provide for approximately a 100% increase in polymer yield while significantly decreasing the amount of polymer cross-linking, i.e. unwanted side-reactions and cross-sections, and

without sacrificing heparin bio-activity. Thus, such coatings are particularly suited for use in small caliber vascular grafts where it is especially important to ensure the patency of these grafts.

The bio-active agent of the present invention is bound to the polymer backbone via a spacer group. The spacer group may include oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides. The length of the spacer, as further discussed herein, is useful in controlling and enhancing the availability of the bio-active agent, since the purpose of the spacer is to tether the bio-active agents such as heparin away from the polymer substrate surface. The spacer group is intended to be hydrophilic in order to take advantage of the natural repulsive forces of the hydrophobic substrate. The spacer group should have reactive functional groups on each end that are capable of reacting with and binding to the polymer backbone and bio-active agent respectively.

Preferably, the spacer group has a hydrophilic functional group on each end, such as a carboxylic acid group or an amine group. An amino end-blocked poly(ethylene oxide), PEO, is a preferred example.

Hydrophilic poly(ethylene oxide) spacers are preferred because they have low interfacial free energy, lack binding sights, and exhibit highly dynamic motion. These characteristics are important because they increase the bio-activity of a PEO-linked bio-active agent, e.g., heparin. See, K.D. Park et al., supra.

The length of the spacer group may be used to control the bio-active agent's activity. It is known in the art that the anti-thrombogenic activity of heparin is increased when it is positioned a certain distance from the substrate to which it is bound. For example, the bioactivity of polymer-spacer-heparin coatings were evaluated as a function of spacer length (as measured by molecular weight) for four different commercially available spacers. A six carbon chain alkyl spacer, a PEO 200, a PEO 1000 and a PEO 4000 were used in this comparison. In this experiment, the polymer-PEO 4000-Heparin-coated surface maintained the highest bio-activity. See, K.D. Park et al., supra. Thus, methods are available in the art for controlling the activity of a polymer-bound bio-active agent. By utilizing such methods, one may determine the optimal length of the spacer. Accordingly, as used herein, "bio-effective distance"

means the distance between the bound bio-active agent and the polymer backbone which corresponds to a desired level of activity in the bio-active agent.

Thus, in the present invention, control over the bio-active agent's activity is achieved by varying the length, e.g., molecular weight, of the spacer group. The 5 spacer group may have a molecular weight of about 100 to about 200,000 daltons (approximately 9-400 atoms). Preferably, the spacer group has a molecular weight of about 200 to about 50,000 daltons. Most preferably, the spacer group has a molecular weight of about 1,000 to about 10,000 daltons. The best results are achieved, however, when the amino end-blocked poly(ethylene oxide) has a molecular weight of 4,000 10 daltons.

In addition to the molecular weight of the spacer, the natural repulsive forces between the hydrophobic surface of the medical device and the hydrophilic spacer helps to tether, or extend the bio-active molecule away from the surface. Thus, these natural repulsive forces also contribute to the increased patency of the grafts of the invention 15 by maximizing the ability of the bio-active agent to interact with its physiological environment.

In accordance with the present invention, a significant reduction of thrombus formation and/or infection associated with the use of medical articles is achieved by combining an anti-thrombogenic and/or anti-infective agent in a coating to be applied 20 to the host-contacting surface(s) of the article. A variety of anti-infective agents as known in the art may be used, including, antibiotics, such as penicillin and antibacterial agents such as silver sulfadiazine. Similarly, a variety of anti-thrombogenic agents known in the art may be used, including, heparin, prostaglandins, urokinase, streptokinase, sulfated polysaccharide, and albumin. In some cases it may be desirable 25 to provide either dual anti-infective or anti-thrombogenic action with two or more agents. Additionally, it may be desirable to combine an anti-infective and an anti-thrombogenic action by combining two or more of these different agents. The invention will be described in terms of the preferred heparin, an anti-thrombogenic agent of known safety and high anti-coagulation activity, with the understanding that 30 the invention contemplates any bio-active agent and specifically any anti-thrombogenic and/or anti-infective agent which may be grafted to the polymer backbone via the spacer by the method of the present invention.

5

An implantable medical device of the invention may be any medical article compatible with a polymer bound bio-active agent coating which, absent the coating, may lead to thrombus formation and/or infection when in contact with a body tissue or fluid. Exemplary of, but not limited to, such devices are vascular access (arterial and venous) catheters, introducers, vascular grafts, urinary catheters and associated articles, such as drainage bags and connectors, and all abdominal cavity drainage tubing, bags and connectors. Thus, in most cases, these devices will contact body fluids, such as, blood, urine, etc., however, the present invention is not limited to such conditions.

10

15

Surface-modified implantable sheet materials are also contemplated by the present invention. Such materials may be manufactured in sheets, layers, lamina, leafs, membranes, films, coatings and the like so that they may be custom fitted to various applications. Examples include, without limitation, surgical mesh, surgical patches, hernia plugs and the like. In accordance with the methods provided herein, such materials may be plasma-primed and then coated with any of the bio-active coatings of the present invention. Thus, commercial quantities of such sheets can be generated for use in a number of different applications.

20

Various shapes and surface characteristics of the polymer substrate as determined by the specific circumstances may also be used in the present invention. Preferred devices are polymeric, most preferably expandable polytetrafluoroethylene (ePTFE) small caliber vascular grafts.

It is contemplated that at least one surface of an implantable medical device be coated by the bio-active coating of the present invention. Multiple surfaces of the medical device, however may be so coated depending on the intended use.

25

30

Certain substrates, such as ePTFE, require plasma treatment with a hydrogen-rich plasma prior to application of the bio-active coating. As previously mentioned, conventional plasma techniques may be employed. Application of the bio-active coating can be performed by dipping, spraying or other techniques. It is preferred that from about 1 to about 10 coatings of the bio-active coating be used. The number of coatings to be used, however, will depend on the substrate surface to be coated and the requirements of the particular situation. Thus, in one embodiment of the present invention, the luminal surface of a small caliber ePTFE vascular graft is first treated with a hydrogen-rich plasma followed by application of one or more coats of a bio-

active coating described herein.

In a further embodiment, the present invention includes a biocompatible backbone polymer having carboxyl functionality or unsaturated functionality, an amine-terminated spacer and a bio-active agent. In this embodiment, a dehydrating agent, such as, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, may be used to facilitate binding of the polymer backbone to one end of the amine terminated spacer and of the bio-active agent to the other non-reacted end of the spacer.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

WHAT IS CLAIMED IS:

- 1) An implantable medical device having at least one hydrophobic surface, said surface having a bio-active coating bound thereto, said bio-active coating containing a polymer backbone bound via an amide or an amine linkage to a first end of a hydrophilic, amine-terminated spacer, said spacer having at least one amine group at each of its first and second ends, said hydrophilic spacer being covalently bound to a bio-active molecule via its second end, said hydrophilic spacer further being repelled by said hydrophobic surface such that the bio-active molecule is extended away from said hydrophobic surface.
5
- 2) The device of claim 1, wherein said device is a vascular graft.
- 3) The device of claim 2, wherein said device is a vascular graft made from a synthetic polymer material selected from the group consisting of PTFE, polyurethane and polyethylene terephthalate.
- 4) The device of claim 1, wherein said bio-active coating further comprises a polymer structure defined by a bio-compatible polymeric backbone and at least one pendant moiety selected from the group consisting of:
$$R^1-R^2-NH-C-R^3,$$
5
wherein R^1 is $O=C-NH$ or NH ; R^2 is a spacer group selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides; and R^3 is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics, antibacterial agents, antiviral agents, their pharmaceutical salts and mixtures thereof.
10
- 5) The device of claim 1 wherein said medical device is an ePTFE vascular graft having a diameter of 5 mm or less.

6) A medical device having a bio-active coating over a body fluid contacting surface of said medical device for contacting body fluids, wherein said body fluid contacting surface is covalently bonded to said bio-active coating, said coating comprising a polymeric structure, said polymeric structure defined by a bio-compatible polymeric backbone and at least one pendant moiety selected from the group consisting of:



wherein R^1 is $O=C-NH$ or NH ; R^2 is a spacer group selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides; and R^3 is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics, antibacterial agents, antiviral agents, their pharmaceutical salts and mixtures thereof.

7) A surface-modified implantable sheet material whose treated surface when exposed to a body fluid is bioactive over extended periods of time comprising:
a hydrophobic substrate material having a plasma induced hydrophilic functionality and a bio-active coating covalently bonded to said substrate material
5 wherein the bio-active coating has a polymeric structure defined by a bio-compatible polymeric backbone and at least one pendant moiety selected from the group consisting of:



wherein R^1 is $O=C-NH$ or NH ; R^2 is a spacer group selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides; and R^3 is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics, antibacterial agents, antiviral agents, their pharmaceutical salts and mixtures thereof.

8) A medical device with at least one hydrophobic surface having a bio-active coating thereon, said bio-active coating being the reaction product of:

5 a) a first reaction comprising reacting in the presence of a first dehydrating agent, a bio-compatible polymer backbone containing one or more functional groups selected from the group consisting of carboxyl functionality, unsaturated functionality and mixtures thereof with a hydrophilic, amine-terminated spacer having at least one amine group at each of its first and second ends, wherein one of said amine groups reacts with said one or more functional groups in said polymer backbone to bond said spacer to said polymer backbone; and

10 b) a second reaction comprising reacting a bio-active agent with a remaining unreacted amine terminated end of said spacer in the presence of a second dehydrating agent to covalently bind said bio-active agent to said spacer.

9) A method of imparting a bio-active coating to a surface of an article which comprises:

5 a) plasma treating a surface of said article whereby hydrophilic groups generated from a gaseous material are introduced onto a surface of said article to provide a hydrophilic environment thereon, and

10 b) contacting said surface with a bio-active coating, said coating being the reaction product of

15 a first reaction comprising reacting in the presence of a first dehydrating agent a biocompatible polymer backbone containing one or more functional groups selected from the group consisting of carboxyl functionality, unsaturated functionality and mixtures thereof with a hydrophilic amine-terminated spacer having a first end and a second end, said first and second ends each having an amine group wherein one of said amine groups reacts with said one or more functional groups on said polymer backbone, and

20 a second reaction comprising reacting a bio-active agent reactive with a remaining unreacted amine-terminated end of said spacer in the presence of a second dehydrating agent to covalently bind said bio-active agent to said spacer.

10) The method of claim 9, wherein said article is a medical device.

11) The method of claim 9, wherein said article is an ePTFE vascular graft having a diameter of 5 mm or less.

12) The method of claim 9, wherein said contacting is selected from the group consisting of dipping, steeping and spraying.

13) The method of claim 9 wherein said contacting includes application of a force to cause said bioactive coating to enter into the interstices of the surface of said device.

14) The method of claim 9, wherein said contacting further comprises applying from about 1 to about 10 layers of the bioactive coating to the surface of the article.

15) A method of coating an ePTFE vascular graft having an inner and outer surface comprising:

a) plasma treating said inner surface and whereby hydrophilic groups generated from a gaseous material are introduced onto said inner surface;

5 b) contacting said inner plasma treated surface with a bio-active coating, said coating being the reaction product of

a first reaction comprising reacting in the presence of a first dehydrating agent a biocompatible polymer backbone containing one or more functional groups selected from the group consisting of carboxyl functionality, unsaturated functionality and mixtures thereof with a hydrophilic amine-terminated spacer having a first end and a second end, said first and second ends each having an amine group wherein one of said amine groups reacts with said one or more functional groups on said polymer backbone, and

10 a second reaction comprising reacting a bio-active agent reactive with a remaining unreacted amine-terminated end of said spacer in the presence of a second dehydrating agent to covalently bind said bio-active agent to said spacer.


- 16) The method of claim 15, wherein said inner surface of said ePTFE vascular graft includes nodes and fibrils.
- 17) The method of claim 15, wherein said fibrils and nodes are resistant to said plasma treatment.
- 18) The method of claim 15, wherein said plasma is a hydrogen-rich plasma.
- 19) The method of claim 15, wherein said bio-active agent is selected from the group consisting of antithrombogenic agents, antibiotic agents, antibacterial agents, antiviral agents, their pharmaceutical salts, and mixtures thereof.
- 20) The method of claim 15, wherein said bio-active agent is selected from the group consisting of heparin, prostaglandins, urokinase, streptokinase, sulfated polysaccharide, albumin, their pharmaceutical salts and mixtures thereof.
- 21) The method of claim 15 wherein said plasma treatment further comprises employing the following parameters in a plasma ionization chamber:
 - a) a gas flow rate of about 1 to 500 ml/minute;
 - b) a chamber pressure of about 0.1 to about 100 torrs;
 - c) a power of about 1 to 700 watts; and
 - d) a sample exposure time of from one minute to about 24 hours.
- 22) A method of imparting a bio-active coating to a surface of an article which comprises:
 - a) plasma treating a surface of said article and a gaseous material in an ionization chamber whereby hydrophilic groups generated from said gaseous material are introduced onto a surface of said article to provide a hydrophilic environment thereon, and
 - b) contacting said surface with a coating composition including a polymeric structure defined by a bio-compatible polymeric backbone and at least one pendant moiety selected from the group consisting of :



wherein R¹ is O=C-NH or NH, R² is a spacer group selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides; and R³ is a bio-active agent selected from the group consisting of antithrombogenic agents, antibiotics agents, antiviral agents, their pharmaceutical salts and mixtures thereof.

23) A method of imparting a bio-active coating to a surface of an article which comprises:

- a) plasma treating said surface and a gaseous material in an ionization chamber whereby hydrophilic groups generated from said gaseous material are introduced onto said surface to provide a hydrophilic environment thereon, and
- b) contacting said surface with a polymer bound bio-active composition represented by the structure:



wherein P is a bio-compatible polymer selected from the group consisting of bio-compatible polymers having carboxyl functionality, unsaturated functionality, and mixtures thereof; R¹ is O=C-NH or NH; R² is a hydrophilic amine-terminated spacer selected from the group consisting of oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides; and R³ is a bio-active agent selected from the group consisting of anti-thrombogenic agents, antibiotic agents, antibacterial agents, their pharmaceutical salts, and mixtures thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/16163

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61L33/00 A61L27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (names of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 10938 A (CASE WESTERN RESERVE UNIVERSITY) 26 May 1994 see the whole document	1-8
Y	US 5 336 518 A (P.V. NARAYANAN ET AL) 9 August 1994	1-23
X	AI-ZHI PIAO ET AL: "HEPARIN IMMOBILIZATION BY SURFACE AMPLIFICATION" ASAIO JOURNAL, vol. 38, no. 3, 1 July 1992, pages 638-643, XP000321590 see the whole document	1,4,6, 8-10,12, 14,22,23
Y	---	1-23
X	---	1-6,8
	---	-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

20 January 1998

27/01/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Fletcher, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/16163

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	EP 0 790 042 A (VASCULAR GRAFT RESEARCH CENTER) 20 August 1997 see page 3, line 6 - page 4, line 11 see page 4, line 25 - line 43 see page 5, line 13 - page 6, line 28	1-23
Y	US 5 132 108 A (P.V. NARAYANAN ET AL) 21 July 1992 cited in the application see the whole document	1-23
A	KI DONG PARK ET AL: "SYNTHESIS AND CHARACTERIZATION OF SPUU-PEO-HEPARIN GRAFT COPOLYMERS" JOURNAL OF POLYMER SCIENCE, POLYMER CHEMISTRY EDITION, vol. 29, no. 12, 1 November 1991, pages 1725-1737, XP000261976 see the whole document	1-23
A	EP 0 263 184 A (TORAY INDUSTRIES) 13 April 1988 see the whole document	1-6,8
A	WO 90 00343 A (CARDIOPULMONICS INC.) 25 January 1990	
A	EP 0 519 087 A (HELETT-PACKARD GMBH.) 23 December 1992	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No PCT/US 97/16163	
---	--

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9410938 A	26-05-94	US 5455040 A		03-10-95
		AU 5613194 A		08-06-94
US 5336518 A	09-08-94	NONE		
EP 0790042 A	20-08-97	JP 9215746 A		19-08-97
		JP 9262282 A		07-10-97
		JP 9276395 A		28-10-97
		JP 9276393 A		28-10-97
		JP 9276394 A		28-10-97
		AU 1268297 A		21-08-97
		CA 2197375 A		16-08-97
US 5132108 A	21-07-92	NL 9201301 A		16-02-94
		US 5486357 A		23-01-96
		US 5409696 A		25-04-95
		US 5591140 A		07-01-97
		US 5244654 A		14-09-93
EP 0263184 A	13-04-88	DE 3782394 A		03-12-92
		WO 8706007 A		09-10-87
		US 5043278 A		27-08-91
WO 9000343 A	25-01-90	US 5262451 A		16-11-93
		AU 627464 B		27-08-92
		AU 3685889 A		05-02-90
		EP 0426686 A		15-05-91
		JP 3504339 T		26-09-91
		JP 5023789 B		05-04-93
		US 5342693 A		30-08-94
		US 5338770 A		16-08-94
		US 5182317 A		26-01-93
EP 0519087 A	23-12-92	DE 69125828 D		28-05-97
		DE 69125828 T		31-07-97
		JP 5220217 A		31-08-93
		US 5451428 A		19-09-95